Arvinas, Inc. presented new preclinical combination data for ARV-393, its investigational PROTAC B-cell lymphoma 6 protein (BCL6) degrader, at the 2025 American Association for Cancer Research (AACR) annual meeting. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas.
The data demonstrated strong synergistic antitumor activity, including complete regressions, when ARV-393 was combined with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors. These results were observed in high grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL) models.
These findings provide a compelling rationale for considering combination strategies and support the continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma. A Phase 1 study of ARV-393 is currently enrolling patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.